

Robert S Mckelvie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1705286/publications.pdf>

Version: 2024-02-01

42
papers

5,524
citations

236925

25
h-index

289244

40
g-index

43
all docs

43
docs citations

43
times ranked

7837
citing authors

#	ARTICLE	IF	CITATIONS
1	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2008, 359, 2456-2467.	27.0	1,663
2	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	27.0	641
3	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	27.0	526
4	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	1.7	503
5	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	27.0	299
6	Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 27-35.	3.9	216
7	The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 168-181.	1.7	176
8	The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care. <i>Canadian Journal of Cardiology</i> , 2011, 27, 319-338.	1.7	139
9	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. <i>Canadian Journal of Cardiology</i> , 2007, 23, 21-45.	1.7	131
10	The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. <i>Canadian Journal of Cardiology</i> , 2010, 26, 185-202.	1.7	125
11	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. <i>Canadian Journal of Cardiology</i> , 2015, 31, 3-16.	1.7	96
12	Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 561-568.	3.9	91
13	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , 2016, 32, 296-310.	1.7	86
14	Sprint training enhances ionic regulation during intense exercise in men. <i>Journal of Physiology</i> , 1997, 501, 687-702.	2.9	82
15	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
16	Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1106-1113.	2.8	67
17	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. <i>Lancet</i> , 2022, 399, 1391-1400.	13.7	67
18	Effects of resistance training combined with moderate-intensity endurance or low-volume high-intensity interval exercise on cardiovascular risk factors in patients with coronary artery disease. <i>Journal of Science and Medicine in Sport</i> , 2015, 18, 637-642.	1.3	62

#	ARTICLE	IF	CITATIONS
19	Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. <i>European Heart Journal</i> , 2003, 24, 1727-1734.	2.2	52
20	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-PRESERVE study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	7.1	52
21	Circulatory Responses to Weight Lifting, Walking, and Stair Climbing in Older Males. <i>Journal of the American Geriatrics Society</i> , 1996, 44, 121-125.	2.6	49
22	Enhanced pulmonary and active skeletal muscle gas exchange during intense exercise after sprint training in men. <i>Journal of Physiology</i> , 1997, 501, 703-716.	2.9	48
23	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. <i>Canadian Journal of Cardiology</i> , 2014, 30, 249-263.	1.7	44
24	Evidence based application of BNP/NT-proBNP testing in heart failure. <i>Clinical Biochemistry</i> , 2015, 48, 236-246.	1.9	39
25	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 20-28.	1.7	35
26	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 478-486.	4.1	21
27	Technology-Enabled Remote Monitoring and Self-Management – Vision for Patient Empowerment Following Cardiac and Vascular Surgery: User Testing and Randomized Controlled Trial Protocol. <i>JMIR Research Protocols</i> , 2016, 5, e149.	1.0	19
28	Brachial Artery Endothelial Responses during Early Recovery from an Exercise Bout in Patients with Coronary Artery Disease. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	18
29	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.	7.1	17
30	The journey of the frail older adult with heart failure: implications for management and health care systems. <i>Reviews in Clinical Gerontology</i> , 2014, 24, 269-289.	0.5	13
31	Canadian Cardiovascular Society Quality Indicators for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1038.e5-1038.e9.	1.7	13
32	The effect of beta-blockade on plasma potassium concentrations and muscle excitability following static exercise. <i>Pflügers Archiv European Journal of Physiology</i> , 1998, 436, 449-456.	2.8	11
33	The Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1566-1569.	1.7	11
34	The role of unregulated care providers in managing heart failure patients in long-term care facilities. <i>Journal of Clinical Nursing</i> , 2017, 26, 849-861.	3.0	9
35	An Update on the Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation and Atrial Flutter. <i>CJC Open</i> , 2019, 1, 198-205.	1.5	9
36	Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. <i>CJC Open</i> , 2020, 2, 321-327.	1.5	8

#	ARTICLE	IF	CITATIONS
37	Development of a patient decision aid for people with refractory angina: protocol for a three-phase pilot study. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 93.	2.4	6
38	The Canadian Heart Failure (CAN-HF) Registry: A Canadian multi-centre, retrospective study of inpatients with heart failure.. <i>CJC Open</i> , 2022, , .	1.5	3
39	The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 245-253.	4.1	1
40	Origins of arterial and femoral venous acidâ€base responses during moderate-intensity bicycling exercise after glycogen depletion in men. <i>Equine and Comparative Exercise Physiology</i> , 2007, 4, 123-133.	0.4	1
41	The CREATE Method for Expressing Continuous Outcome Data in Absolute Terms for Use in Patient Treatment Decision Aids. <i>Medical Decision Making</i> , 2015, 35, 959-966.	2.4	0
42	Abstract 3640: Diabetes Mellitus is Associated with Increased Risk of Fatal and Non-Fatal Cardiovascular Events in Heart Failure Patients with Preserved Ejection Fraction - Findings From the Irbesartan in Heart Failure with Preserved Systolic Function Trial. <i>Circulation</i> , 2007, 116, .	1.6	0